Search

EHA-THD Joint membership

We are pleased to inform that EHA and the Türk Hematoloji Derneği (THD) have joined forces and are offering you the possibility of an EHA-THD Joint Membership in 2023.

Read more

Harnessing new developments in genomics to improve outcome for children with poor prognosis leukemia

At the 19th Congress of the European Hematology Association (EHA), we will learn about the state-of-the-art in management of childhood AML.

Read more

Highlights from the SWG

Events
The ERIC International Preceptorship, Realizing Precision Medicine in CLL: Why and How
Stresa, Italy
November 17–18, 2023
PublicationsRecent ERIC publications include:

The evolving landscape of COVID-19 and post-COVID condition in patients with chronic lymphocytic leukemia
Other malignancies in the history of CLL: an international multicenter study conducted…

Read more

EHA-SWG on AAA a virtual meeting with a worldwide approach covering all aspects of the disease!

Live days: April 29-30, 2021

Content available: April 22, 2021 – May 29, 2021

Chair: Prof Dr C Dufour

Junior and senior hematologists from all over the world gathered on April 29-30, 2021 for the live days of the EHA-SWG Scientific Meeting on…

Read more

Appointment of new EHA Managing Director

The Hague (Netherlands), January 16, 2023. The European Hematology Association (EHA) is pleased to welcome its new Managing Director, Ignacio Quiles Lara, who took up the post on January 9.

Read more

Patient Advocacy Committee

Current committee members
Derek Elston, United Kingdom (Chair)
Samantha Nier (Switzerland) (Vice-chair)
Members representing a Patient Advocacy Organization

Organization
Member

Acute Leukaemia Advocates Network (ALAN)

Samantha Nier

CCI Europe

Anita Kienesberger

CLL Advocates Network (CLLAN)

Pierre Aumont

CML Advocates Network

Jan Geissler

European Federation of Associations of Patients with Haemochromatosis (EFAPH)

Dag Erling Stavik

European Haemophilia…

Read more

The root of evil: pre-leukemic clones that survive chemotherapy are linked to a higher risk of leukemia recurrence

Acute myeloid leukemia (AML) is an aggressive form of blood cancer. Treatment with intensive chemotherapy often leads to a period of freedom from overt disease called a remission. However, recurrence of the disease is common.

Read more